The Syqe Inhaler includes selective 100 micro-gram exact dosing, real-time thermal and flow controllers as well as lung interfacing and wireless connectivity. This new level of precision will allow patients to regain their quality of life.
Syqe Medical chairman Dr. Eytan Hyam states in an interview that “Thanks to the Syqe inhaler, we are effectively moving from cannabis use to cannabis treatment. For doctors, the inhaler solves the problem of prescribing plants for smoking, and offers a solution for patients in that, for the first time, they will be able to receive a precise dose of medical cannabis.”
This first of its kind inhaler minimizes the psychoactive effects while providing pain relief. “This device gives us physicians the confidence to prescribe cannabis in the same way as we prescribe other drugs today,” said Seth Kindler M.D., the company’s chief science officer.
The inhaler will be distributed by Teva to different hospitals and clinics under the terms of the deal. Eventually this will become world wide. Israeli Health Ministry is expected to give Teva approval for domestic use in the new year.
Recently, Syqe Medical has provided Haifa’s Rambam Hospital in Israel with the inhaler for test stuies. This hospital is the first in the world to prescribe this device. Marijuana is allowed for medical use in Israel by special permission by the Israeli Ministry of Health.